UpHill Health

Compliance Analysis and Clinical Training for Hospitals

[UpHill Health @UpHill_Health]

💥🚀 Great news in @ojeconomico!

Together with Luz Saúde and Universidade da Beira Interior, UpHill will develop addPath, a project that uses #ArtificialIntelligence to optimize clinical pathways' implementation and dissemination. 💪

https://t.co/h9s7tglIFR

[UpHill Health @UpHill_Health]

Highlighted by @davsrodrigues this week on Update #Covid_19 review 👇👇👇
"Overall, we show that #SARSCoV2 infection induces a robust antigen-specific, long-lived humoral immune response in humans."
https://t.co/V38Wau3Yc4

[UpHill Health @UpHill_Health]

A reflection by our co-founder and Head of Partnerships, Luís Patrão, on the evolution of #medicaltraining, to read on @dinheiro_vivo.👇
https://t.co/h2ZInPlC15

[UpHill Health @UpHill_Health]

🦠‼️ "Saliva sampling seems to be a similarly sensitive and less costly alternative that could replace nasopharyngeal swabs for the collection of clinical samples for #SARSCoV2 testing."

https://t.co/oaDnRJ37Kc

[UpHill Health @UpHill_Health]

🤔Meaning that control strategies for #COVIDー19 should be altered, taking into account the prevalence and transmission risk of #asymptomatic #SARS_CoV_2 infection.

[UpHill Health @UpHill_Health]

🦠‼️ What is the asymptomatic infections' impact on #COVIDー19 dissemination? @davsrodrigues, our VP for Medical Content, analyzed a recent study published at @AnnalsofIM with relevant conclusions.
👉 https://t.co/W0exO3i1cV

[UpHill Health @UpHill_Health]

📢 "(...) at least one-third of SARS-CoV-2 infections are asymptomatic. Longitudinal studies suggest that nearly three-quarters of persons who receive a positive PCR test result but have no symptoms at the time of testing will remain asymptomatic."

[UpHill Health @UpHill_Health]

‼️A clear effect of the vaccines against the B.1.1.7 variant was found.

[UpHill Health @UpHill_Health]

💉‼️ New information about the real-world effectiveness of the #PfizerVaccine and #astrazenecavaccine!
https://t.co/5yqQv5utx2

[UpHill Health @UpHill_Health]

➡️156.930 adults aged 70 years and older who reported symptoms of #COVIDー19 between December 8th, 2020 and February 19th, 2021 and were successfully linked to vaccination data in the National Immunisation Management System.

[UpHill Health @UpHill_Health]

Both #vaccines showed similar effects and vaccination with either one dose of BNT162b2 or ChAdOx1-S was associated with a significant reduction in symptomatic COVID-19 in older adults and with further protection against severe disease.

[Instituto Ricardo Jorge @irj_pt]

Resultados da segunda fase do Inquérito Serológico COVID-19 mostram aumento da imunidade contra a COVID-19 em Portugal, mas deve ser prestada particular atenção aos grupos etários e regiões menos afetadas pela epidemia. ➡️ https://t.co/l625d5Uwy0 #ISNCOVID19 #INSA #SNS #Saúde

[UpHill Health @UpHill_Health]

How do UpHill's clinical pathways impact healthcare workers' daily practice? 👇

[UpHill Health @UpHill_Health]

This phenomenon has major repercussions to highly exposed individuals like #healthcareworkers: they should continue to use #Masks and also be vaccinated, even after infection.
👉 https://t.co/yHjlTK3wKm

[UpHill Health @UpHill_Health]

🦠 This report reveals that #reinfection can occur in apparently normal hosts and that the reinfecting virus may be similar, if not identical, to the original #SARSCoV2.

[UpHill Health @UpHill_Health]

The authors conclude, with high confidence in the evidence, that the use of ACEIs or ARBs does not increase the risk for SARS-CoV-2 infection. The evidence is so clear that they will retire this key question from their living review.
👉 https://t.co/ocoVR16jdt

[UpHill Health @UpHill_Health]

@AnnalsofIM has summarized the question "Is the use of ACEIs and ARBs Associated with More Severe COVID-19 Illness?" 👇

[UpHill Health @UpHill_Health]

@davsrodrigues, our VP for Medical Content, highlights a simple idea: we are in a global race between the speed of vaccination and population immunization, and the emergence of mutations that can offer evolutionary advantages to the virus.

[UpHill Health @UpHill_Health]

‼️ This study describes two cases of clinically active COVID-19 infection in people who have been vaccinated. Both cases showed positive results 19 and 37 days after receiving the second doses of mRNA vaccines.
https://t.co/tpbzmUj2jU

[UpHill Health @UpHill_Health]

The tests found that one of the patients was infected with a variant that was "related, but distinct" from the variants of concern B.1.1.7 (UK) and B.1.526 (NY), and both patients had mutations of potential clinical relevance.